lazetinib.jpeg
lazetinib.jpeg

Lazertinib

$100.00

Lazertinib (sold as Lazcluze) is an oral kinase inhibitor approved by the FDA in August 2024. It is used in combination with amivantamab as a first-line, chemotherapy-free treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have specific EGFR mutations

Lazertinib (sold as Lazcluze) is an oral kinase inhibitor approved by the FDA in August 2024. It is used in combination with amivantamab as a first-line, chemotherapy-free treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have specific EGFR mutations